What is the long-term trend for Halozyme Therapeutics's research and development expense?

Over 2 years (2023 to 2025), Halozyme Therapeutics's research and development expense has grown at a 3.3% compound annual growth rate (CAGR), from $76.36M to $81.49M.

Halozyme Therapeutics HALO Research and development expense

Research and development expense at other companies

AbbVieABBV

——

AmgenAMGN

——

ViatrisVTRS

——

Spyre Therapeutics, Inc.SYRE

——

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's research and development expense?: Halozyme Therapeutics (HALO) reported research and development expense of $20.37M in Q4 2025.
How has Halozyme Therapeutics's research and development expense changed year-over-year?: Halozyme Therapeutics's research and development expense increased by 3.1% year-over-year, from $19.76M to $20.37M.
What is the long-term trend for Halozyme Therapeutics's research and development expense?: Over 2 years (2023 to 2025), Halozyme Therapeutics's research and development expense has grown at a 3.3% compound annual growth rate (CAGR), from $76.36M to $81.49M.